Alnylam Pharmaceuticals
ALNY
#642
Rank
S$41.77 B
Marketcap
$323.91
Share price
-6.36%
Change (1 day)
41.22%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total liabilities

Total liabilities on the balance sheet as of September 2024 : S$5.59 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total liabilities are S$5.59 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Alnylam Pharmaceuticals - Total liabilities on balance sheet (from 2003 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31S$5.34 B7.72%
2022-12-31S$4.96 B20.24%
2021-12-31S$4.13 B30.58%
2020-12-31S$3.16 B145.29%
2019-12-31S$1.28 B245.94%
2018-12-31S$0.37 B22.07%
2017-12-31S$0.30 B-38.42%
2016-12-31S$0.49 B187.8%
2015-12-31S$0.17 B-9.03%
2014-12-31S$0.18 B-0.47%
2013-12-31S$0.19 B1.39%
2012-12-31S$0.18 B-11.59%
2011-12-31S$0.21 B-29.88%
2010-12-31S$0.30 B-28.93%
2009-12-31S$0.42 B-15.51%
2008-12-31S$0.50 B18.92%
2007-12-31S$0.42 B612%
2006-12-31S$59.54 M-2.2%
2005-12-31S$60.88 M86.94%
2004-12-31S$32.57 M-69.02%
2003-12-31S$0.10 B191.95%
2002-12-31S$36.01 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
S$0.73 B-86.94%๐Ÿ‡บ๐Ÿ‡ธ USA
S$10.88 B 94.50%๐Ÿ‡บ๐Ÿ‡ธ USA
S$3.19 B-42.99%๐Ÿ‡บ๐Ÿ‡ธ USA
S$0.78 B-85.99%๐Ÿ‡บ๐Ÿ‡ธ USA
S$7.96 M-99.86%๐Ÿ‡บ๐Ÿ‡ธ USA
S$80.58 B 1,339.91%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
S$81.60 B 1,358.14%๐Ÿ‡ซ๐Ÿ‡ท France
S$47.44 B 747.75%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel